The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in ...
The Federal Trade Commission sued the three dominant pharmacy-benefit managers in the United States, alleging they inflated the cost of insulin by using their position as middlemen in the U.S.
Results that may be inaccessible to you are currently showing.